Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis
Open Access
- 2 September 2025
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 493
Abstract
Colorectal cancer is one of the most common malignancies worldwide, with liver metastasis being one of its primary metastatic patterns and a significant cause of death. For most patients with unresectable colorectal cancer liver metastasis, a comprehensive treatment strategy that includes chemotherapy and targeted therapy is the primary therapeutic strategy. However, significant breakthroughs in immune therapy for liver metastasis have yet to be achieved. In this article, we summarize the characteristics of the immune microenvironment in colorectal cancer liver metastases and the mechanisms of immune resistance. Additionally, we compile recent clinical trial results on immune combination strategies and biomarker studies and discuss the prospects for applying immune checkpoint inhibitors in the treatment of colorectal cancer liver metastasis.Keywords
Funding Information
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0501600)
This publication has 62 references indexed in Scilit:
- Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal CancerJAMA Network Open, 2023
- Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)eClinicalMedicine, 2023
- Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancerCell Host & Microbe, 2023
- Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior ChemotherapyJAMA Oncology, 2023
- Immune phenotypic linkage between colorectal cancer and liver metastasisCancer Cell, 2022
- Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liverCancer Cell, 2021
- Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Comparison of Immune Microenvironment Between Colon and Liver Metastatic Tissue in Colon Cancer Patients with Liver MetastasisDigestive Diseases and Sciences, 2020
- Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinomaCancer Immunology, Immunotherapy, 2019
- The role of hepatic macrophages in liver metastasisCellular Immunology, 2018